Access Statistics for Diego Useche

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are patents signals for the IPO market? An EU–US comparison for the software industry 0 0 0 0 0 0 7 40
Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital 0 0 0 0 2 2 7 18
Empirical Economic Analysis of Orphan Drug Innovation 0 0 0 0 2 2 2 13
Empirical Economic Analysis of Orphan Drug Innovation 0 0 0 0 0 1 2 22
Empirical Economic Analysis of Orphan Drug Innovation 0 0 0 0 1 2 7 14
Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation 0 0 0 0 3 3 8 41
Empirical economic analysis of orphan drug legislation impact on innovation 0 0 0 0 1 1 3 419
Highly skilled and well connected: Migrant inventors in cross-border M&As 0 0 0 0 5 5 9 21
Highly skilled and well connected: Migrant inventors in cross-border M&As 0 0 0 0 1 5 13 28
Highly skilled and well connected: Migrant inventors in cross-border M&As 0 0 0 0 3 4 19 37
Highly-skilled migrants and Cross-border M&A: Firm-level evidence 0 0 0 0 0 1 6 34
Highly-skilled migrants and Cross-border M&A: Firm-level evidence 0 0 0 48 0 1 14 102
Highly-skilled migrants and Cross-border M&A: Firm-level evidence 0 0 0 0 0 0 5 9
Highly-skilled migrants and Cross-border M&A: Firm-level evidence 0 0 0 0 1 2 7 12
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 0 0 0 16 2 2 8 125
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021 0 0 0 0 3 3 6 14
Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies 0 0 0 0 3 3 8 26
Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies 0 0 0 0 1 1 11 57
Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms 0 0 0 7 1 3 7 26
Total Working Papers 0 0 0 71 29 41 149 1,058

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are patents signals for the IPO market? An EU–US comparison for the software industry 0 0 2 45 6 9 36 198
Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital 0 0 2 10 1 2 22 71
Highly skilled and well connected: Migrant inventors in cross-border M&As 0 0 1 24 2 5 24 118
Patenting Behaviour and the Survival of Newly Listed European Software Firms 0 0 0 8 2 6 17 54
Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms 0 0 1 9 4 6 13 44
Total Journal Articles 0 0 6 96 15 28 112 485

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 0 0 0 14 4 7 15 100
Total Chapters 0 0 0 14 4 7 15 100

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-05-06